Former FDA Chief Offers Three Avenues for Regulating Disruptive Medical Technologies

To regulate new medical device technologies, the FDA should rely on familiar regulatory processes to review low-risk activities while adopting a more attentive approach that devotes greater resources to high-risk activities, according to a former agency commissioner.
Source: Drug Industry Daily